Search research articles
Contact Us
Filters
Showing results (231-240 of 487) with videos related to
Page
of 49
Sort By:
Oncotarget
|
July 11, 2018
Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors
Ishwaria M Subbiah, Chad Tang, Arvind Rao, et al.
Cold Spring Harbor Molecular Case Studies
|
August 27, 2020
Dual inhibition of BRAF and mTOR in <i>BRAF</i><sup></sup> -mutant pediatric, adolescent, and young adult brain tumors
Shiraj Sen, Ryuma Tanaka, Soumen Khatua, et al.
Current Oncology (Toronto, Ont.)
|
June 26, 2024
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy
Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, et al.
Cancer Letters
|
January 8, 2025
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model
Ujjwol Khatri, Mohamed A Gouda, Shriya Pandey, et al.
Cancers
|
September 28, 2023
Dosimetry of a Novel <sup>111</sup>Indium-Labeled Anti-P-Cadherin Monoclonal Antibody (FF-21101) in Non-Human Primates
Gregory Ravizzini, William Erwin, Louis De Palatis, et al.
JCO Clinical Cancer Informatics
|
January 18, 2019
High-Throughput Architecture for Discovering Combination Cancer Therapeutics
Matt Gianni, Yong Qin, Geert Wenes, et al.
Current Oncology Reports
|
March 28, 2018
Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology
Marc El Beaino, Jason Roszik, John A Livingston, et al.
Journal of Hematology & Oncology
|
August 3, 2014
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial
Vivek Subbiah, Funda Meric-Bernstam, Gordon B Mills, et al.
Oncotarget
|
June 27, 2013
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications
Yunyun Jiang, Filip Janku, Vivek Subbiah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation
Jia Liu, Juliana Beal, Niamh Coleman, et al.
Page
of 49
Search research articles
Search
Showing results (231-240 of 487) with videos related to
Sort By:
Page
of 49
Oncotarget
|
July 11, 2018
Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors
Ishwaria M Subbiah, Chad Tang, Arvind Rao, et al.
Cold Spring Harbor Molecular Case Studies
|
August 27, 2020
Dual inhibition of BRAF and mTOR in <i>BRAF</i><sup></sup> -mutant pediatric, adolescent, and young adult brain tumors
Shiraj Sen, Ryuma Tanaka, Soumen Khatua, et al.
Current Oncology (Toronto, Ont.)
|
June 26, 2024
Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy
Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, et al.
Cancer Letters
|
January 8, 2025
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model
Ujjwol Khatri, Mohamed A Gouda, Shriya Pandey, et al.
Cancers
|
September 28, 2023
Dosimetry of a Novel <sup>111</sup>Indium-Labeled Anti-P-Cadherin Monoclonal Antibody (FF-21101) in Non-Human Primates
Gregory Ravizzini, William Erwin, Louis De Palatis, et al.
JCO Clinical Cancer Informatics
|
January 18, 2019
High-Throughput Architecture for Discovering Combination Cancer Therapeutics
Matt Gianni, Yong Qin, Geert Wenes, et al.
Current Oncology Reports
|
March 28, 2018
Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology
Marc El Beaino, Jason Roszik, John A Livingston, et al.
Journal of Hematology & Oncology
|
August 3, 2014
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial
Vivek Subbiah, Funda Meric-Bernstam, Gordon B Mills, et al.
Oncotarget
|
June 27, 2013
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications
Yunyun Jiang, Filip Janku, Vivek Subbiah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation
Jia Liu, Juliana Beal, Niamh Coleman, et al.
Page
of 49